The significance of EGFR mutations remains unclear since there is evidence that, in non-small-cell lung cancer (NSCLC), mutations in the TK domain of EGFR are predictive for the response to gefitinib [25]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.